ClinicalTrials.gg
RecruitingNCT07216560Updated Nov 2, 2026

First-in-human Study of 7MW4911 in GI Cancer

A Phase 1/2 interventional study of 7MW4911 in GI Cancers, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 2, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

02

Conditions studied

  • GI Cancers
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 and above
  2. 0-1
  3. ≥ 3 months
  4. Advanced or gastrointestinal cancer that has progressed after standard of care.
  5. Disease progression after the most recent treatment regimen
  6. At least one according to v1.1
  7. Provision of or fresh biopsy.
  8. Adequte hematologic funciton, liver function and renal function.
  9. Comply with requirements

Exclusion criteria

Exclusion Criteria:

  1. Other concurrent in the recent 3 years except for adequately treated carcinoma in situ.
  2. Active, untreated or symptomatic
  3. Effusions that require frequent drainage
  4. Patients with active disease, except for type I diabetes, hypothyroidism and other autoimmune disease that does not require systemic treatment.
  5. Severe respiratory disease that required hospitalization in the last 28 days.
  6. Significant and uncontrolled cardiovascular disease or events in the 6 months prior to study drug administration
  7. Poorly controlled blood glucose with fasting blood glucose above 10mmol/L
  8. Recipient of stem cell transplant or organ transplant
  9. Active or /C infection. Infection requiring systemic IV in the 14 days prior to study drug administration.
  10. Experiencing toxicities from prior anti-cancer therapies that have not recovered to grade 0-1, except for alopecia and endocrinopathies.
  11. Prohibited treatment and treatment that requires

    1. Has received another Topo-I payload ADC, and/or another CDH17 targeting therapy.
    2. Received other cancer therapy within 5 half-lives or 21 days prior to study drug administration.
    3. Major surgeries within 28 days prior to study drug administration
    4. therapy within 28 days prior to study drug administration
    5. Systemic treatment with agents within 28 days prior to first drug administration. Physiological dose of , topical glucocorticoid are allowed.
    6. Use of strong inhibitor or inducer
  12. Known to 7MW4911 or components of the formulation
  13. Abuse of narcotic or psychoactive drugs
  14. Pregnant or breastfeeding women
  15. Other circumstances or conditions where the investigator judges to be unsuitable for study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    7MW4911

    Drug: 7MW4911

Interventions

  • Drug7MW4911

    study drug

06

What researchers measure

Primary outcomes

  1. Incidence and rates of adverse events

    To assess the safety and tolerability of 7MW4911 in patients with advanced colorectal cancer and other advanced gastrointestinal tumors

    Time frame: Up to approximately 2 years

  2. MTD, RED, and RP2D

    To determine the maximum tolerated dose (MTD) and recommended expansion dose (RED) or the recommended phase II dose (RP2D)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Tmax of 7MW4911

    time to maximum concentration of 7MW4911 in blood

    Time frame: up to 3 months

  2. Cmax of 7MW4911

    maximum concentration of 7MW4911 in bloood

    Time frame: up to 3 months

  3. Half life of 7MW4911

    time to decrease of 7MW4911 concentration by 50% in blood

    Time frame: up to 3 months

  4. Area under the curve of 7MW4911

    Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t)

    Time frame: up to 3 months

  5. Objective response rate

    proportion of patients whose turmor response meet the criteria of complete response or partial response

    Time frame: Up to approximately 2 years

  6. Progression-free survival

    Duration in months from enrollment to first disease progression

    Time frame: up to approximately 2 years

  7. Immunogenicity of 7MW4911

    Incidence and rates of ADA

    Time frame: Up to approximately 2 years

Other outcomes

  1. Biomarker for efficacy

    To explore the relationship between the expression of CDH17 in tumor tissues and other biomarkers and the efficacy and safety of 7MW4911 in patients with advanced colorectal cancer and selected gastrointestinal tumor types

    Time frame: Up to approximately 2 years

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 14, 2025
StartActual
Jan 13, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: x•••@mabwell.com · •••2260→m•••@mabwell.com · •••4911; w•••@mabwell.com→e•••@mabwell.com. See the current contact
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Contact Study contact changed: x•••@mabwell.com · •••2260→m•••@mabwell.com · •••4911; w•••@mabwell.com→e•••@mabwell.com. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07216560
Responsible party
Sponsor
First posted
Oct 14, 2025
Start date
Jan 13, 2026
Primary completion
Jul 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Matthew Brobeck
Contact
matthew.brobeck@mabwell.com
(801) 201.4911
Eric Li
Contact
eric.li@mabwell.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion